Epigenetics Startup Completes $22 Million Series B Funding Round

Posted on June 14, 2010
Filed Under Healthcare |

Constellation Pharmaceuticals, Inc., the biopharmaceutical company developing new drugs targeting epigenetic regulation of the human genome, raised $22 million in a Series B financing round. The financing round was led by SR One, the independent corporate healthcare venture capital arm of GlaxoSmithKline, with participation from existing investors Third Rock Ventures, The Column Group, Venrock, and Altitude Life Science Ventures. This Series B financing brings the total amount of capital raised by Constellation in the two years since its founding to $54 million.

Epigenetics is the study of inherited changes in phenotype (appearance) or gene expression caused by mechanisms other than changes in the underlying DNA sequence. These changes may remain through cell divisions for the remainder of the cell’s life and may also last for multiple generations. However, there is no change in the underlying DNA sequence of the organism; instead, non-genetic factors cause the organism’s genes to behave (or “express themselves”) differently.

Proceeds from the financing will be used to advance the development of Constellation’s pipeline of compounds towards the clinic. These funds will also enable Constellation to continue applying its innovative epigenetics product engine to probe multiple classes of novel drug targets involved in chromatin regulation and disease.

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a new field of science that focuses on selective regulators of gene function and expression. The Company’s academic founders represent the core thought leaders in epigenetics and are responsible for numerous key advances in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at .

Sphere: Related Content